Deutsche Bank set a €70.00 ($81.40) price target on Bayer (FRA:BAYN) in a report released on Monday, April 1st, Borsen Zeitung reports. The brokerage currently has a neutral rating on the healthcare company’s stock.
BAYN has been the topic of several other research reports. Sanford C. Bernstein set a €86.00 ($100.00) target price on Bayer and gave the company a buy rating in a research report on Wednesday, March 20th. JPMorgan Chase & Co. set a €70.00 ($81.40) price objective on Bayer and gave the stock a neutral rating in a research report on Thursday, March 28th. Independent Research set a €52.50 ($61.05) price objective on Bayer and gave the stock a sell rating in a research report on Friday, March 29th. UBS Group set a €110.00 ($127.91) price objective on Bayer and gave the stock a buy rating in a research report on Tuesday, January 8th. Finally, Nord/LB set a €72.00 ($83.72) target price on Bayer and gave the company a neutral rating in a research report on Wednesday, February 27th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating and twelve have given a buy rating to the company’s stock. The stock has an average rating of Hold and an average price target of €81.80 ($95.12).
BAYN traded up €0.29 ($0.34) during trading on Monday, hitting €61.71 ($71.76). The company’s stock had a trading volume of 2,495,741 shares. Bayer has a twelve month low of €91.58 ($106.49) and a twelve month high of €123.82 ($143.98).
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
See Also: Limitations of the P/E Growth ratio
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.